The case involved a clinical trial of Akero's only product, a drug candidate aimed at treating a liver disease. It's the ...

The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high ...

Here is how Akero Therapeutics, Inc. (AKRO) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the ...

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Akero Therapeutics Inc. advanced stock charts by Barron's. View 1AKRO historical stock data and compare to other stocks, and exchanges.

Investing.com - Akero Therapeutics (NASDAQ:AKRO), a $4.1 billion market cap biotech company with notably strong financials including more cash than debt, is in a stronger competitive position ...